Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction

Novartis International AG / Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• The unique optical design of the ACTIVEFOCUS^(TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses
   

The lens is based on the proven AcrySof^® IQ toric IOL platform that delivers unrivaled rotational stability[1]
 

This extends the market-leading AcrySof^® IQ platform to a broader population of the nearly 2 million cataract patients with treatable levels of astigmatism who undergo cataract surgery each year[2]

Basel, March 23, 2017 - Alcon, the global leader in eye care and a division of Novartis, has received approval from the US Food and Drug Administration (FDA) for its AcrySof® IQ ReSTOR® +2.5 Multifocal Toric intraocular lens (IOL) with ACTIVEFOCUS(TM) optical design for patients undergoing cataract surgery who choose to address their astigmatism and presbyopia at the same time. The unique optical design of the ACTIVEFOCUS(TM) toric lens delivers both crisp, clear distance vision and a range of vision for patients who desire less dependence on glasses. The ACTIVEFOCUS(TM) toric IOL is the only multifocal toric IOL in which the central portion is 100 percent dedicated to distance vision[3],[4]. Previous presbyopia-correcting IOL designs tend to compromise on distance vision in order to provide patients with a range of vision.

"Presbyopic cataract patients with astigmatism have had limited options in the past," said Sergio Duplan, Region President, North America for Alcon. "Alcon's ACTIVEFOCUS^(TM) toric IOL is a breakthrough for these patients, correcting astigmatism and allowing them to achieve uncompromised distance vision with an increased range of vision at the same time."

The ACTIVEFOCUS^(TM) toric IOL is also engineered for stability. Toric IOLs perform optimally if they stay on axis to correct the astigmatism. In a retrospective study of IOL orientation data,  the AcrySof^® IQ toric IOL platform was 2.5 times less likely to rotate than the leading competitor lens^*[1]. Additionally, the AcrySof^® IQ toric platform is the market leader with cataract surgeons implanting more than 1.7 million AcrySof^® IQ toric IOLs to date[5].